VITRAKVI is FDA-indicated to treat solid tumors

By Brian Buntz | July 21, 2021

Bayer‘s Vitrakvi is a kinase inhibitor that is FDA indicated to treat adult and pediatric patients with solid tumors. Specifically, FDA indicates it for solid tumors with the following criteria:

Presence of a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation.
Metastatic or where surgical resection is likely to result in severe morbidity.
Without satisfactory alternative treatments or that have progressed following treatment.

FDA approved the drug for this indication under its accelerated approval program. The agency notes that continued approval for this indication may require further data from confirmatory trials.

Filed Under: Oncology
Tagged With: Bayer, FDA, kinase inhibitor, VITRAKVI

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.